Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Assets (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Non-Current Assets data on record, last reported at $624.8 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 84.04% year-over-year to $624.8 million; the TTM value through Dec 2025 reached $2.0 billion, down 5.7%, while the annual FY2025 figure was $624.8 million, 84.04% up from the prior year.
  • Non-Current Assets reached $624.8 million in Q4 2025 per PTCT's latest filing, down from $635.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.1 billion in Q2 2022 and bottomed at $339.0 million in Q1 2025.
  • Average Non-Current Assets over 5 years is $767.4 million, with a median of $734.0 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: crashed 49.86% in 2024, then surged 84.04% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $983.7 million in 2021, then increased by 2.86% to $1.0 billion in 2022, then tumbled by 33.08% to $677.1 million in 2023, then plummeted by 49.86% to $339.5 million in 2024, then skyrocketed by 84.04% to $624.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $624.8 million in Q4 2025, $635.9 million in Q3 2025, and $361.3 million in Q2 2025.